A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer

Neoplasms Clinical Trial

Official title:

An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01335269
• Other study ID #: 1300.2
• Secondary ID: 2010-024609-10
• Status: Completed
• Phase: Phase 1
• First received: April 7, 2011
• Last updated: December 8, 2015
• Start date: July 2011
• Est. completion date: December 2015

Study information

• Verified date: December 2015
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health CanadaNetherlands: Central Committee Research Involving Human Subjects
• Study type: Interventional

Clinical Trial Summary

The primary objective of this trial is to determine the safety and tolerability of BI 853520 monotherapy by defining the maximum tolerated dose (MTD) and recommending the dose for further trials in the development of this compound.

Secondary objectives are

• determination of the pharmacokinetic (PK) profile;

• exploratory pharmacodynamic analysis; and

• collection of preliminary data on anti-tumour efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: December 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Inclusion criteria

1. Patients with a confirmed diagnosis of advanced, measurable or evaluable, nonresectable and/or metastatic non-hematologic malignancy, which has shown to be progressive in the last 6 months as demonstrated by serial imaging

2. Patients who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not amenable to established treatment options

3. Tumour tissue must be available for the determination of E-cadherin expression (archived tissue or fresh biopsy).

4. Recovery from reversible toxicities (alopecia excluded) of prior anti-cancer therapies (CTCAE grade < 2)

5. Age = 18 years

6. Life expectancy = 3 months

7. Written informed consent in accordance with International Conference on Harmonisation/Good Clinical Practice (ICH/GCP) and local legislation, including consent for PK samples, for using an archived tumour sample for determination of Ecadherin status, for reviewing previous tumour scans (and for providing skin biopsies, in patients in dose finding phase enrolled before protocol amendment 03)

8. Eastern Cooperative Oncology Group (ECOG), R01-0787) performance score 0-1

Additional inclusion criteria in the expansion phase:

9. Patients must have measurable progressive disease within the last 6 months, according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (version 1.1, R09-0262)

10. deleted

11. Patients must be willing to provide paired tumour biopsies for PD determination. Refer to section 5.6.3

12. Patients should fit into one of the categories described below:

I. Metastatic adenocarcinoma of the pancreas Patients should have preferably received at least one line of systemic treatment for metastatic disease and preferably not more than 2 prior regimens for metastatic disease.

II. Platinum-resistant ovarian carcinoma, defined as recurrence within 6 months after completion of prior platinum-based chemotherapy Patients should have received preferably no more than 5 previous lines of systemic treatment for metastatic disease.

III. Oesophageal carcinoma Patients with oesophageal carcinoma of adenocarcinoma- or squamous cell histology who have received preferably not more than 2 previous lines of systemic treatment for metastatic disease.

IV. Soft tissue sarcoma Patients should preferably have received no more than 2 previous lines of systemic treatment for metastatic disease.

Exclusion criteria:

• Serious concomitant non-oncological disease/illness

• Active/symptomatic brain metastases

• Second malignancy

• Pregnancy or breastfeeding

• Women or men who are sexually active and unwilling to use a medically acceptable method of contraception.

• Treatment with cytotoxic anti-cancer-therapies or investigational drugs within four weeks of the first treatment with the study medication

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BI 853520
BI 853520 once daily in a dose escalation schedule

Locations

Country	Name	City	State
Canada	1300.2.1002 Boehringer Ingelheim Investigational Site	Hamilton	Ontario
Canada	1300.2.1001 Boehringer Ingelheim Investigational Site	Toronto	Ontario
Netherlands	1300.2.31003 Boehringer Ingelheim Investigational Site	Amsterdam
Netherlands	1300.2.31001 Boehringer Ingelheim Investigational Site	Rotterdam
Netherlands	1300.2.31002 Boehringer Ingelheim Investigational Site	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Canada,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of the MTD. It will be defined by the occurrence of dose-limiting toxicities (DLT) during the first treatment cycle of each patient in the dose finding phase		After the first 28 days of treatment	No
Secondary	Cmax (maximum measured concentration of the analyte in plasma) after first dose		up to 48 hours	No
Secondary	AUCt,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t after administration of the first dose)		up to 48 hours	No
Secondary	Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) after the last dose in cycle 1		up to 24 hours	No
Secondary	AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) after the last dose in cycle 1		up to 24 hours	No
Secondary	Disease control rate (CR or PR or SD per RECIST v1.1) )		up to 39 months	No
Secondary	Duration of disease control (measured from drug start date to the date of disease progression for patients who had CR or PR or SD during treatment)		up to 39 months	No
Secondary	Objective response rate (CR or PR per RECIST v1.1)		up to 39 months	No
Secondary	Tumour shrinkage (in millimetre) defined as change from baseline to the minimum post-baseline sum of diameters of target lesions.		up to 39 months	No
Secondary	Pharmacodynamic assessment: phosphorylated and total PTK2 (FAK) modulation in tumour biopsies		baseline, day 22 and day 28	No